As the world prepares to deal with the second wave of Covid-19, which has already begun in many countries, questions have arisen about how medical devices markets, including the transcatheter aortic valve replacement (TAVR) market, will handle the impact for a second time.
It has been almost six months since the World Health Organization (WHO) declared a global pandemic, and Covid-19’s initial impact on medical device markets has become well understood. When the pandemic first began in most countries in March and April, elective and non-urgent procedures were largely put on hold or even cancelled.
